NCT02915354View on ClinicalTrials.gov

Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Spondylitis, AnkylosingRecurrence
Interventions
DRUG

Etanercept

Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.

Trial Locations (1)

510630

Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02915354 - Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study | Biotech Hunter | Biotech Hunter